Going-concern and liquidity shortfall
The company states it may cease operations if it cannot raise sufficient capital.
- Scope
- Cash on hand, future R&D, and ability to continue as a public company
- Materiality
- high
Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing immunotherapies for cancer. The company has historically worked on early-stage product candidates and is now seeking new candidates and licensing or acquisition opportunities to rebuild its pipeline.
0.00
0.00
| % | |
|---|---|
| Immunotherapy development | 0% Early-stage programs aimed at developing cancer immunotherapies and related product candidates. |
| Pipeline licensing and acquisition | 0% Rights acquisition and licensing activities used to source new therapeutic candidates. |
| Advisory services | 100% Limited advisory and related services performed under service agreements such as the Oncotelic MSA. |
The company does not appear to have a broad commercial customer base yet, as it remains focused on development-stage...
- Licensing and acquisition partnersprimary
Biotech or pharma counterparties that may provide product candidates or rights for Mosaic to develop.
- Advisory services clientssecondary
Organizations such as Oncotelic that purchase advisory and related services for studies and projects.
- Capital providersprimary
Equity and debt investors that fund operations because the company has limited operating cash flow.
- Future oncology end usersemerging
Patients, physicians, and healthcare systems that would use approved immunotherapies if development succeeds.
The company is based in the United States and its reported activity is centered there...
- •Headquartered in the United States
- •Reported operations and financing activity are U.S.-centric
- •No country-level revenue disclosure was provided
- •Exposure is mainly to U.S. capital markets and regulation
Mosaic's strategy is to preserve liquidity while seeking new product candidates and rights that can rebuild a viable...
01
Source new oncology assetsshort-term
The company needs new candidates to create a development pipeline and future value.
02
Secure additional capitalshort-term
Operations and R&D cannot scale without external financing.
03
Rebuild development activitymedium-term
Limited cash has forced the company to delay and scale back programs.
The company faces substantial going-concern and financing risk because it has limited cash, no committed funding plan,...
Financing dilution and restrictive debt terms
Management expects to fund operations through equity and/or debt, both of which may be costly.
- Scope
- Existing shareholders and future operating flexibility
- Materiality
- high
Pipeline sourcing and development failure
Value depends on identifying and advancing new product candidates or licensed rights.
- Scope
- Research and development strategy
- Materiality
- high
Biotech clinical and regulatory risk
Immunotherapy development is uncertain and subject to trial, approval, and commercialization setbacks.
- Scope
- Future product viability
- Materiality
- medium
Going-concern assessment
Can influence disclosure, asset recoverability, and investor perception
Convertible note accounting
Creates non-cash interest expense and possible dilution
Accrued compensation and operating liabilities
Affects working capital and reported operating cash flow
Advisory service revenue recognition
Affects other income and comparability across periods
: 28.4.2026